Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Recce Pharma

Recce Pharmaceuticals (ASX: RCE)

Last close As at 01/11/2024

AUD0.45

▲ −0.03 (−5.32%)

Market capitalisation

AUD109m

Recce Pharmaceuticals is developing novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis, burn wound infections, urinary tract infections/urosepsis and diabetic foot infections.

The WHO estimates that sepsis leads to c 11 million deaths each year. Sepsis affects 1.7 million people in the United States annually and costs the healthcare system US$57bn in inpatient costs. In our view, there are significant opportunities for treatments that may reduce morbidity or hospital utilisation. Recce announced an A$10m equity financing in July that is expected to extend its runway into FY26.

Latest Insights

View More

Healthcare | edison tv

Recce Pharmaceuticals – executive interview

Healthcare | Update

Recce Pharmaceuticals — Taking a closer look at diabetic foot infections

Healthcare | Update

Recce Pharmaceuticals — Advances on several fronts

Healthcare | Update

Recce Pharmaceuticals — R&D advance (A$11.18m) extends runway
Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.
Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • James Graham

    CEO

  • Daniel Astudillo

    Head of marketing

  • Dr John Prendergast

    Chairman

Balance Sheet

Forecast net debt (A$m)

7.2

Forecast gearing ratio (%)

78

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (12.1) 1.1 4.4
Relative (10.9) (0.1) (13.6)
52 week high/low A$0.7/A$0.4

Financials

Recce Pharmaceuticals is a clinical-stage, Australian biotech company developing a novel class of broad-spectrum synthetic anti-infective drugs to which, so far, all tested bacteria have been unable to develop resistance. This would be a very desirable trait given widespread concerns about antimicrobial resistance. The lead indication for RECCE 327 (R327) is sepsis, a substantial area of unmet need with significant mortality and high costs of care. Recce is also assessing its intravenous formulation in complicated urinary tract infections, with a Phase II study planned in H2 CY24. Topical formulations of R327 are also being evaluated for diabetic foot infections, for which a Phase III program is expected to start in Q3 CY24, and also for burn wound infections.

Y/E Dec Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 3.1 (10.9) (11.0) (6.31) N/A N/A
2023A 4.3 (12.8) (13.1) (7.55) N/A N/A
2024E 5.8 (16.3) (17.2) (8.98) N/A N/A
2025E 9.6 (12.8) (14.4) (6.68) N/A N/A

Research

Update

Healthcare

Recce Pharmaceuticals — Taking a closer look at diabetic foot infections

Update

Healthcare

Recce Pharmaceuticals — Advances on several fronts

Healthcare

edison tv

Recce Pharmaceuticals – executive interview

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free